ReCode Therapeutics launched on Thursday with an OrbiMed- and Colt Ventures-led $80 million series A round to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology. The company was formed...

Eikonizo aims to shore up axonal transport to treat neurodegenerative diseases, starting with ALS; and to de-risk its programs, the company is developing a companion PET tracer to confirm target engagement in vivo.   The...

A trio of Shire veterans launched OncoOne on Wednesday with a €13 million series A round and a batch of biologics against oxidized MIF, a highly selective tumor antigen that was abandoned by the pharma...

Indapta is sidestepping genome engineering for its universal NK cells, a strategy that not only reduces manufacturing costs but also broadens the number of cancer patients it could treat relative to genetically edited allogeneic NK...

Danish newco Twelve Bio is building a CRISPR-Cas12a toolbox comprising a suite of Cas12a variants that are more efficient, precise and safe to use than the wild type Cas12a enzyme for both diagnostic and therapeutic...

First-in-class mAbs against activated dendritic cells from Australian newco Kira could block the inflammation and immune response associated with GvHD and autoimmune diseases without the risk of infection that accompanies broad immunosuppression. Founding CEO Dan...

AiCure is combining a decade’s worth of research into real-world patient behavior with an artificial intelligence platform to optimize patient adherence to treatments in clinical trials. Lack of patient compliance to long-term treatments can lead...

Lava’s bispecific mAbs targeting γδ T cells could match the potency of other T cell engaging technologies while offering a larger therapeutic window. The company joins a growing group of biotechs focused on γδ T...

WindMIL is developing cancer therapies using bone marrow-derived T cells, which could be more persistent than tumor-infiltrating lymphocytes and hit a broader range of antigens than CAR therapies engineered with peripheral blood T cells. The...

Montis launched with €8.4 million and a concept that puts an immuno-oncology spin on the tumor vasculature, marking the second company seeded by oncology-focused Droia Ventures in as many weeks. Droia, which teamed up with...

UC Berkeley spinout C. Light thinks its retina tracking technology could capture early signs of neurological diseases and variability across different patients. “We’re looking to change neurology from a reactionary area of medicine to a...

With its platform of carbohydrate-binding proteins, Pneumagen is co-opting a pathogenic tool for interacting with host cells to block infections and adapting the technology for use against cancer. Both viruses and bacteria can interact with...

A trio of Weill Cornell and Sloan Kettering researchers have launched Volastra with $12 million in seed funding to develop therapies targeting chromosomal instability -- a driver of cancer metastasis. Polaris Partners led the seed...

Serentrix is looking to revive a well-known pain target that has been largely abandoned by drug developers after antagonists against it led to side effects. Early clinical testing by Serentrix LLC has shown that the...

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative...